The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Feasibility and clinical outcomes of imatinib personalized dosing in gastrointestinal stromal tumor patients.
 
Maud van der Kleij
No Relationships to Disclose
 
Eline Giraud
No Relationships to Disclose
 
Niels Guchelaar
No Relationships to Disclose
 
Kim Westerdijk
No Relationships to Disclose
 
Marinda Meertens
No Relationships to Disclose
 
Martijn Koolen
Stock and Other Ownership Interests - Pharming NV
 
Roos Bleckman
No Relationships to Disclose
 
Hans-Martin Otten
No Relationships to Disclose
 
Helle-Brit Fiebrich
No Relationships to Disclose
 
Stijn Koolen
No Relationships to Disclose
 
Hans Gelderblom
Research Funding - Abbisko Therapeutics (Inst); AmmaxBio (Inst); Blueprint Medicines (Inst); Deciphera (Inst); InhibRx (Inst); Ipsen (Inst); SynOX (Inst)
Travel, Accommodations, Expenses - Abbisko Therapeutics (Inst); Merck (Inst)
 
Dirk Jan A.R. Moes
No Relationships to Disclose
 
An Reyners
Research Funding - Merck (Inst); Tesaro (Inst)
 
Daan Touw
No Relationships to Disclose
 
Ron Mathijssen
Stock and Other Ownership Interests - Galapagos NV
Research Funding - Astellas Pharma (Inst); Bayer Holding (Inst); Boehringer Ingelheim (Inst); Cristal Therapeutics (Inst); Deuter Oncology (Inst); Nordic Bioscience (Inst); Novartis (Inst); Pamgene (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst)
 
Nielka Van Erp
Research Funding - Astellas Pharma (Inst); Ipsen (Inst)
 
Ingrid Desar
No Relationships to Disclose
 
Alwin Huitema
No Relationships to Disclose
 
Neeltje Steeghs
Consulting or Advisory Role - Boehringer Ingelheim (Inst); Bristol-Myers Squibb/Celgene; Ellipses Pharma (Inst); GlaxoSmithKline; GlaxoSmithKline (Inst); Incyte; Incyte (Inst)
Research Funding - Abbvie (Inst); Actuate Therapeutics (Inst); Amgen (Inst); Anaveon (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CellCentric (Inst); Cogent Biosciences (Inst); Crescendo Biologics (Inst); Daiichi Sankyo/Lilly (Inst); Daiichi Sankyo/Lilly (Inst); Deciphera (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Iambic (Inst); IDRx (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Kling Biotherapeutics (Inst); Lixte Biotechnology (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Molecular Partners (Inst); Novartis (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche (Inst); Sanofi (Inst); Zentalis (Inst)
 
Dutch Pharmacology Oncology Group
No Relationships to Disclose